Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3011 IT in advanced solid tumors
NCT05602792Phase 2Unknown
- Sponsor
- ImmVira
- Start
- Apr 2020
- Primary completion
- Jul 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of MVR-T3011 in solid tumor, sarcoma, head and neck squamous cell carcinoma (HNSCC), breast cancer, esophageal cancer, sponsored by ImmVira. Status: unknown.
02
Drugs
MVR-T3011
03
Conditions
solid tumorsarcomahead and neck squamous cell carcinoma (HNSCC)breast canceresophageal cancer
Beyond the preview
Go deeper on NCT05602792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602792.